Madelaine (Mattie) A. Feldman, MD

Opinion

Abuse of the Safety-Net 340B Drug Pricing Program: Why Should Physicians Care?

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: November 18, 2024

“What was once a program to uplift underserved communities now risks becoming a case study in how good intentions can go astray without accountabil...

Opinion

‘Reform School’ for Pharmacy Benefit Managers: How Might Legislation Help Patients?

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: September 17, 2024

Dr. Madelaine A. Feldman writes how pending federal legislation targeting PBMs might affect patients’ access to medications and also delink drug li...

News

Fed Worker Health Plans Ban Maximizers and Copay Accumulators: Why Not for the Rest of the US?

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: July 29, 2024

The US federal government refrains from enforcing bans on copay accumulators and maximizers for the American public, but it does ban them in its pl...

Opinion

Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: May 16, 2024

Legislative or regulatory action is unlikely to address the current negative reimbursement situation for office-based infusion of certain biosimila...

Opinion

ERISA Health Plan Lawsuits: Why Should We Care?

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: March 15, 2024

Chances are high that you have patients employed by companies with self-funded health insurance plans that could be harming them both physically an...

Opinion

Biosimilar Business Deals Keep Up ‘Musical Chairs’ Game of Formulary Construction

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: January 17, 2024

The FTC has frowned upon manufacturers owning PBMs and allowing them to construct their own formularies in the past, so why is it allowing CVS Heal...

News

Prescription drug affordability boards: Another quick fix with unintended consequences?

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: November 17, 2023

Provisions included in some states’ prescription drug affordability boards may allow them to set upper payment limits for medications, potentially ...

News

Insurer’s foray into AI-based ‘shared savings’ program creates ethical problems

Author:: Madelaine (Mattie) A. Feldman, MD

Publish date: September 20, 2023

Liability and ethical concerns arise from a recently proposed voluntary program from Blue Cross and Blue Shield of North Carolina that would sugges...